Second Genome develops novel medicines by integrating microbiome and host biology through a drug-discovery platform that identifies novel targets and candidate drugs. Its data analysis techniques enable identification of microbes and microbial biomarkers that influence disease states. The company combines these discovery capabilities with drug development expertise to accelerate the rapid discovery of therapeutic options across a range of microbiome-related diseases. Second Genome intends to use the new funds to accelerate translation of its microbiome discoveries into a pipeline of clinical opportunities. Leadership cited in the report includes newly appointed CEO Glenn Nedwin, Ph.D., CSO Karim Dabbagh, Ph.D., and chairman and co-founder Corey Goodman, Ph.D. Second Genome leverages a microbiome discovery platform that combines genomics technologies, computational biology, and phenotypic screening to identify novel proteins, peptides, and metabolites that play causal roles in human disease and wellness. The company is led by CEO Peter DiLaura and is based in South San Francisco, CA. It closed a $42.6M Series B and has raised $59M in total to date. Second Genome plans to use the funds to expand its Microbiome Discovery Platform across indications tied to barrier function, insulin sensitivity, and immune regulation. The company will also advance the clinical investigation of SGM-1019, a small-molecule inhibitor targeting a microbiome-mediated pathway, through human proof-of-concept studies. The platform-driven approach supports discovery of molecules intended to address inflammation and pain in ulcerative colitis and other indications. Second Genome develops a Microbiome Signature Discovery Platform to identify and validate microbiome signatures rapidly and accurately. The company focuses on microbiome-based personalized medicine for gastrointestinal diseases and disorders, including IBS, IBD, antibiotic-associated diarrhea, and necrotizing enterocolitis. It partners with academic researchers and manufacturers of novel and existing therapies — including developers of probiotic, nutraceutical, and pharmaceutical products — to study therapy impacts on the gut microbiome and develop response signatures. The company intends to use the new funding to further develop its personalized medicine solutions for GI conditions. Second Genome was founded in 2009 as PhyloTech and is led by President and CEO Peter DiLaura and co-founder and Chairman Dr. Corey Goodman. The company is based in San Francisco, CA.

Total raised

$56M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2016